Gemcitabine

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW):263.2

Gemcitabineは一種の有効で、特異性的なデオキシシチジン(deoxycytidine)類似物で、、化学療法として使用されることです。

サイズ 価格 在庫  
JPY 18718.43 あり
JPY 13966.83 あり

カスタマーフィードバック(4)

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabineは一種の有効で、特異性的なデオキシシチジン(deoxycytidine)類似物で、、化学療法として使用されることです。
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M{\WOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMECwOFU5KG6P NF;aWpVUSU6JRWK=
ES4 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTrTWM2OD1yLkCwNFY2OyCwTR?= MUnTRW5ITVJ?
ACHN NFTE[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3VbWpKSzVyPUCuNFAxQDh5IH7N NIrGdGNUSU6JRWK=
KYSE-510 NEDXR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrH[|JiUUN3ME2wMlAxODl5NTDuUS=> M3PET3NCVkeHUh?=
EW-7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMECyOVghdk1? NX\XdldWW0GQR1XS
BFTC-905 NYPaSnlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL6eXBKSzVyPUCuNFA2OTVibl2= M3vRbnNCVkeHUh?=
KE-37 NYSyOoROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEC1OlEhdk1? MoXlV2FPT0WU
SBC-5 NHPv[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULmcWJvUUN3ME2wMlAxPTdibl2= M3zVbnNCVkeHUh?=
NKM-1 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEC3NFkhdk1? M3zpRXNCVkeHUh?=
RH-1 M4XXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEC3NVghdk1? MorGV2FPT0WU
ALL-PO NUfodG5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[yb2k3UUN3ME2wMlAxQDNibl2= NX:wXlNkW0GQR1XS
QIMR-WIL M4PMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEC4PVQhdk1? NUTIZYxxW0GQR1XS
A375 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\3XnVyUUN3ME2wMlAxQTl3IH7N NYnrcYc1W0GQR1XS
SIG-M5 NEL6clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml73TWM2OD1yLkCxNFQhdk1? MXXTRW5ITVJ?
KGN NEXsRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEGwPEBvVQ>? NH3PWoVUSU6JRWK=
EW-13 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vxVGlEPTB;MD6wNVEzKG6P NUnLRoRNW0GQR1XS
NCI-SNU-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHhZ2VKSzVyPUCuNFE3KG6P M2TK[XNCVkeHUh?=
PSN1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH30cZJKSzVyPUCuNFE3PSCwTR?= MnXlV2FPT0WU
HUTU-80 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrzcm0zUUN3ME2wMlAyPjZibl2= MYnTRW5ITVJ?
EW-16 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTSfHpJUUN3ME2wMlAzOyCwTR?= MYDTRW5ITVJ?
786-0 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEKzJI5O M1HpU3NCVkeHUh?=
ES1 NXTSSpNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLpTWM2OD1yLkCyOlghdk1? MULTRW5ITVJ?
RKO NXXLNVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LydmlEPTB;MD6wNlc6KG6P NUTCZlJFW0GQR1XS
ESS-1 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3t[W9KSzVyPUCuNFI5PiCwTR?= NFjNU2tUSU6JRWK=
SK-UT-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnBO3h6UUN3ME2wMlAzQTdibl2= Mkj5V2FPT0WU
LB2241-RCC NWHHWJlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrmTWM2OD1yLkCzNVghdk1? NWS0WWhvW0GQR1XS
CHL-1 NXHJWnR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGzTWM2OD1yLkCzNlQhdk1? MX\TRW5ITVJ?
SW1783 NFnDS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHabpFmUUN3ME2wMlA{OzZibl2= MWHTRW5ITVJ?
MEL-JUSO MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3lco5KSzVyPUCuNFM6OSCwTR?= M{S1cnNCVkeHUh?=
HT-29 NG\LRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHJS5ZIUUN3ME2wMlA1OTNibl2= MWLTRW5ITVJ?
SNG-M NIfERmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3mxWWlEPTB;MD6wOFI2KG6P MWPTRW5ITVJ?
TE-15 NUmyclhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrTTWM2OD1yLkC0OlQhdk1? NXz0TFRvW0GQR1XS
HOS M2rBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjvWFNJUUN3ME2wMlA1QCCwTR?= MkX6V2FPT0WU
BB65-RCC NVLp[5dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEWxNkBvVQ>? M1TncnNCVkeHUh?=
HCE-4 NXrlOFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPKTWM2OD1yLkC1Nlghdk1? NYfPPGdRW0GQR1XS
MHH-ES-1 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfwTWM2OD1yLkC1N|Ehdk1? NIfn[lZUSU6JRWK=
RPMI-7951 MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKzcpVRUUN3ME2wMlA2PDFibl2= NVnsc5R2W0GQR1XS
IST-SL2 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPpUVdKSzVyPUCuNFU5PCCwTR?= MWnTRW5ITVJ?
CMK NVToR|RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jaNWlEPTB;MD6wOVg3KG6P MoPxV2FPT0WU
GR-ST NHPNe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEW5OUBvVQ>? NH\ucnlUSU6JRWK=
NALM-6 NFr1fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwME[yNkBvVQ>? NHXYTG5USU6JRWK=
RPMI-6666 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwME[1NkBvVQ>? MWPTRW5ITVJ?
LC-2-ad NYXJPIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7yTotIUUN3ME2wMlA3PTNibl2= MUTTRW5ITVJ?
ARH-77 NWLxUnVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWzNoE4UUN3ME2wMlA4OTFibl2= NEmwVYhUSU6JRWK=
IST-MEL1 NUHUVoVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKwOGZnUUN3ME2wMlA4OjZibl2= NVzrO5lTW0GQR1XS
SW1710 NGOzXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PaRWlEPTB;MD6wO|UyKG6P MkT6V2FPT0WU
DEL Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DERmlEPTB;MD6wPFg4KG6P MlKzV2FPT0WU
AGS M1rXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEmwNkBvVQ>? M4npVnNCVkeHUh?=
NCI-H2122 NETQdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzzTHFKSzVyPUCuNFk1PiCwTR?= NU[yTmRPW0GQR1XS
HSC-4 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMUCyJI5O NIHPUWZUSU6JRWK=
AM-38 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PS[GlEPTB;MD6xNlEhdk1? M{HhR3NCVkeHUh?=
769-P MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjVTWM2OD1yLkGyN{BvVQ>? MVvTRW5ITVJ?
RT-112 M1fkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr3bYJTUUN3ME2wMlEzPyCwTR?= NYGz[XlUW0GQR1XS
MCF7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC3TpJqUUN3ME2wMlE{PiCwTR?= M2ribXNCVkeHUh?=
IGROV-1 NUWwN|NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv4[YNFUUN3ME2wMlE1PSCwTR?= NYnvb3NPW0GQR1XS
OCI-AML2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTJUo9KSzVyPUCuNVQ4KG6P M1f1UnNCVkeHUh?=
NCI-H1299 NEWyOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\0dJpFUUN3ME2wMlE2PyCwTR?= NFHvfJdUSU6JRWK=
A431 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMUizJI5O NGnS[ldUSU6JRWK=
SW982 NEnGc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7BbWxKSzVyPUCuNlE{KG6P M{POZnNCVkeHUh?=
BB30-HNC NV2ydnJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjDUlBKSzVyPUCuNlMyKG6P NIPlOZhUSU6JRWK=
ACN MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMkS0JI5O NGrXSpBUSU6JRWK=
647-V NGHBSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[2TWM2OD1yLkK0PEBvVQ>? NXLJ[mRtW0GQR1XS
SK-PN-DW MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMk[2JI5O MWLTRW5ITVJ?
LCLC-97TM1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMk[3JI5O NXfYPVNKW0GQR1XS
LB1047-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;obWlEPTB;MD6yOlkhdk1? MoDjV2FPT0WU
A2780 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMkegcm0> MnO3V2FPT0WU
C-33-A NGf4RplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPtTWM2OD1yLkK3N{BvVQ>? M4\oTnNCVkeHUh?=
NCI-H2228 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrzNXZQUUN3ME2wMlMyPCCwTR?= NXnyWZFqW0GQR1XS
TE-5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX0U3hKSzVyPUCuN|E3KG6P M2f1XHNCVkeHUh?=
HC-1 NE\aUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwM{K3JI5O M2jwfnNCVkeHUh?=
SK-MES-1 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[5TWM2OD1yLkOyPEBvVQ>? MUfTRW5ITVJ?
NCI-H1355 M1nH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLoV5hKUUN3ME2wMlM5OSCwTR?= M13a[XNCVkeHUh?=
YKG-1 NELkO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNEG5JI5O NFjQc|FUSU6JRWK=
RS4-11 NHfpSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL2fWRKSzVyPUCuOFM{KG6P NUPKZZZ[W0GQR1XS
Daoy M4fwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrEWJlPUUN3ME2wMlQ2PiCwTR?= MnvlV2FPT0WU
A3-KAW Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXsTWM2OD1yLkW1NUBvVQ>? M4\hRXNCVkeHUh?=
SK-MEL-30 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfFfWJKSzVyPUCuOVU1KG6P MYDTRW5ITVJ?
U031 NVO2cmR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjRVYhKSzVyPUCuOVY2KG6P Ml\YV2FPT0WU
SK-LMS-1 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f5ZWlEPTB;MD61O|ghdk1? NYjUU5VPW0GQR1XS
ES6 M2q2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHFTWM2OD1yLkW4OkBvVQ>? NHPhOnNUSU6JRWK=
EoL-1-cell MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwNkG2JI5O M{PvUXNCVkeHUh?=
NCI-H2009 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwNkG5JI5O MUXTRW5ITVJ?
A4-Fuk MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXrUYpGUUN3ME2wMlYzPiCwTR?= NXv6OIpKW0GQR1XS
KYSE-270 NGfzZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfsTWM2OD1yLk[zOEBvVQ>? M2\aXnNCVkeHUh?=
SK-LU-1 NEP0NIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrOUVdRUUN3ME2wMlY2PSCwTR?= M{jBNXNCVkeHUh?=
SW872 NXW0O41ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjHZYlIUUN3ME2wMlc3PSCwTR?= NF3XRWhUSU6JRWK=
ES8 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vjOWlEPTB;MD63PEBvVQ>? MUjTRW5ITVJ?
G-402 M3XrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwN{i0JI5O NUfuVZFwW0GQR1XS
ATN-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwOEC3JI5O NFLVOotUSU6JRWK=
DoTc2-4510 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGzVJB6UUN3ME2wMlkxOSCwTR?= M2PFSHNCVkeHUh?=
MES-SA MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwOUC1JI5O MmHnV2FPT0WU
SF268 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzlXHdMUUN3ME2wMlkzPyCwTR?= MWHTRW5ITVJ?
SF539 NWXBcXRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;yZmlEPTB;MT6wNkBvVQ>? Mof3V2FPT0WU
NB69 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK3TIpKSzVyPUGuNFUhdk1? M1vxb3NCVkeHUh?=
8505C NYfndGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[2dXpKSzVyPUGuNFYhdk1? Mnm5V2FPT0WU
CAL-12T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHSTWM2OD1zLkC4JI5O MmrGV2FPT0WU
BHY MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;nS2lEPTB;MT6xOEBvVQ>? MkjyV2FPT0WU
LB647-SCLC M2Pqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXaTWM2OD1zLkG4JI5O M1fkO3NCVkeHUh?=
CAL-62 NVrT[o81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf1TWM2OD1zLkKyJI5O NIPCbGlUSU6JRWK=
MEG-01 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjYTWM2OD1zLkK3JI5O NHex[JBUSU6JRWK=
MG-63 NVvyOnhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL6TWM2OD1zLkOzJI5O M{HVeHNCVkeHUh?=
SW620 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\DTWM2OD1zLkO1JI5O MWfTRW5ITVJ?
A388 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L2ZmlEPTB;MT6zOkBvVQ>? NEDadWNUSU6JRWK=
BCPAP M32xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ezcGlEPTB;MT60OUBvVQ>? NWLKfox6W0GQR1XS
P30-OHK M3Ps[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjqfXZ6UUN3ME2xMlQ3KG6P M3;1OnNCVkeHUh?=
Ca9-22 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILURplKSzVyPUGuOVQhdk1? MYTTRW5ITVJ?
VMRC-RCZ MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwNUSgcm0> MkjZV2FPT0WU
LOXIMVI M3O3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwNjDuUS=> NEfiXndUSU6JRWK=
L-540 NWTL[nJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvtS3g3UUN3ME2xMlYhdk1? NITXZYlUSU6JRWK=
NTERA-S-cl-D1 M1\wPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33oPGlEPTB;MT62OEBvVQ>? M3;GOnNCVkeHUh?=
MFH-ino NVLOenU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoriTWM2OD1zLk[2JI5O M{PhPHNCVkeHUh?=
Calu-6 NEf2RWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiybop2UUN3ME2xMlc{KG6P MlP3V2FPT0WU
HEL M{XCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHJR4FKSzVyPUGuO|khdk1? NX3kSXpoW0GQR1XS
CAL-33 NITKdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHsWVZMUUN3ME2xMlg6KG6P M4Sx[XNCVkeHUh?=
HSC-3 M3TIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qwV2lEPTB;MT65NUBvVQ>? MlzZV2FPT0WU
KU812 M2\KdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPocnpKSzVyPUGuPVEhdk1? NVfJNnNbW0GQR1XS
EB2 M2fV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJwMEGgcm0> MX7TRW5ITVJ?
SR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwMUKgcm0> M1XUVXNCVkeHUh?=
NCI-H2087 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwMUSgcm0> MmGwV2FPT0WU
H4 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwMUigcm0> MUfTRW5ITVJ?
EW-1 NX\wUIVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64cJBjUUN3ME2yMlIzKG6P Mom4V2FPT0WU
MC-IXC M4HMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPQTWM2OD1{LkK2JI5O Mn6wV2FPT0WU
NCI-H727 NFrTd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXhbHJKSzVyPUKuOVEhdk1? NVnGbmVWW0GQR1XS
MRK-nu-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TjV2lEPTB;Mj61O{BvVQ>? NUnmUHAzW0GQR1XS
COLO-668 NUf1eoY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M125WWlEPTB;Mj62OkBvVQ>? MWrTRW5ITVJ?
CGTH-W-1 NWC5c4JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwN{Kgcm0> NGiybXlUSU6JRWK=
CHP-212 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJwN{Wgcm0> MkHGV2FPT0WU
GI-1 NW\lfY9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwN{[gcm0> MlzvV2FPT0WU
HCC1806 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTJTWM2OD1{LkmxJI5O MoXVV2FPT0WU
HLE M1npbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf4WGNDUUN3ME2zJI5O NGPX[VBUSU6JRWK=
HSC-2 NXHXb|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ETYpKSzVyPUOuNFMhdk1? NY\DcFhvW0GQR1XS
DMS-273 NHW1S4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTNwMEegcm0> MXTTRW5ITVJ?
DU-4475 NFvzTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrnflNKSzVyPUOuNVQhdk1? MoL3V2FPT0WU
LXF-289 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;oc2lEPTB;Mz6zNUBvVQ>? NW\ybodnW0GQR1XS
PANC-03-27 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjZTWM2OD1|LkWxJI5O Mki5V2FPT0WU
GAMG M1z4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDmTWM2OD1|Lke0JI5O NYnI[ZptW0GQR1XS
NCI-H522 M1POeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRwM{Sgcm0> MV\TRW5ITVJ?
SW626 MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofETWM2OD12LkS2JI5O MWDTRW5ITVJ?
HT-144 M17Kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHxUItKSzVyPUSuPVIhdk1? M3:4dnNCVkeHUh?=
MEL-HO NYHhSFN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC0cJlKSzVyPUWuNVYhdk1? MV;TRW5ITVJ?
BE-13 NWfzWYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvxem9LUUN3ME21MlIyKG6P M4HC[HNCVkeHUh?=
VA-ES-BJ MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXtWY1KSzVyPUWuNlYhdk1? M4XqdXNCVkeHUh?=
NCI-H441 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvjcW5KSzVyPUWuOkBvVQ>? NH\XbIVUSU6JRWK=
KP-4 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTVwNkGgcm0> MXHTRW5ITVJ?
LoVo MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vwe2lEPTB;NT63NUBvVQ>? NGrWZo9USU6JRWK=
HT-1080 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ibWlEPTB;NT64N{BvVQ>? NVrTW5pSW0GQR1XS
GB-1 M4TEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDITWM2OD13Lki0JI5O MorkV2FPT0WU
IA-LM MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTxbm0xUUN3ME21MlkyKG6P MUPTRW5ITVJ?
8-MG-BA NUDQfFE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLNTWM2OD13LkmzJI5O NH\qZ|VUSU6JRWK=
SK-HEP-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rGc2lEPTB;Nj6xOEBvVQ>? Mm\SV2FPT0WU
697 NVzwfpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TPb2lEPTB;Nj6yOUBvVQ>? MlzyV2FPT0WU
KYSE-450 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G2emlEPTB;Nj6zNkBvVQ>? NFHQTmpUSU6JRWK=
HCC2998 M3ruXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZwM{Sgcm0> NIHQdoFUSU6JRWK=
HD-MY-Z NHvqZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonrTWM2OD14Lk[4JI5O MVHTRW5ITVJ?
OS-RC-2 NXL3ZnRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTZwNkigcm0> Mmq4V2FPT0WU
SF126 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfrTWM1UUN3ME23MlA2KG6P NF\vcopUSU6JRWK=
Ca-Ski MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37qNWlEPTB;Nz6wPUBvVQ>? NV64UpZqW0GQR1XS
NCI-H358 M3:wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPQdJVWUUN3ME23MlE3KG6P MoTHV2FPT0WU
J82 M13mV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH4TWM2OD15LkSxJI5O NXPSdo1wW0GQR1XS
NCI-H2342 NU\PToFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnxd3RxUUN3ME23MlY{KG6P M2PiRnNCVkeHUh?=
OVCAR-8 NFu1ToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXxZWViUUN3ME23Mlkhdk1? NHToVG1USU6JRWK=
TE-8 M3zwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRThibl2= NVnFSoNKW0GQR1XS
ETK-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT1S4lKSzVyPUiuNFghdk1? NXG4PItkW0GQR1XS
HAL-01 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDYNnB1UUN3ME24MlIhdk1? M1nyVnNCVkeHUh?=
KYSE-150 Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGraZnBKSzVyPUiuOFchdk1? NFrKbmFUSU6JRWK=
NCI-H810 NVnLXGVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRThwNU[gcm0> MlPpV2FPT0WU
ONS-76 M1y1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PvUmlEPTB;OD62PEBvVQ>? NYDLVY1MW0GQR1XS
NMC-G1 NVzMWWp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX31S2s2UUN3ME24Mlc3KG6P MYrTRW5ITVJ?
C3A MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor5TWM2OD16Lki0JI5O Mn64V2FPT0WU
PA-1 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRThwOUmgcm0> NF30WnFUSU6JRWK=
SH-4 NFrvTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfSSZNKSzVyPUmuNFIhdk1? NXjqPY4xW0GQR1XS
EFO-27 NUf0dJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Mdo9KSzVyPUmuNFUhdk1? MnnKV2FPT0WU
CAPAN-1 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDQZYM{UUN3ME25MlI{KG6P M{PXXnNCVkeHUh?=
DU-145 M2jCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3meFNrUUN3ME25MlI6KG6P NE\n[XJUSU6JRWK=
A101D MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH0XIlKSzVyPUmuN|chdk1? NIHRbmtUSU6JRWK=
ST486 NV\ZcHloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTlwNEGgcm0> NYK3[JFkW0GQR1XS
NCI-H1437 NGXFb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfFTWM2OD17LkSyJI5O MYTTRW5ITVJ?
HGC-27 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrKXZhHUUN3ME25MlYhdk1? Mn[xV2FPT0WU
8305C NXf3W|UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTlwNkSgcm0> MWjTRW5ITVJ?
OCUB-M M4i5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD5eVhbUUN3ME2xNE4xOyCwTR?= M2LOW3NCVkeHUh?=
COLO-679 M3rH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHLTWM2OD1zMD6wO{BvVQ>? NVPRNZVsW0GQR1XS
Detroit562 Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjxTWM2OD1zMD60NkBvVQ>? M3rWTXNCVkeHUh?=
A204 M3zrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTUTWM2OD1zMT6xOkBvVQ>? NETHemdUSU6JRWK=
NCI-H1734 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;EZ2ZKSzVyPUGxMlI6KG6P MnS2V2FPT0WU
MC-CAR NH;0UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe5[282UUN3ME2xNU42QCCwTR?= MVXTRW5ITVJ?
NCI-H2170 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvQTWM2OD1zMT65O{BvVQ>? MkHNV2FPT0WU
NCI-SNU-5 NWjaRm5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL0TWM2OD1zMj6xN{BvVQ>? NV7UbI54W0GQR1XS
HCE-T NEG1XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHYVGJxUUN3ME2xNk41OiCwTR?= MUTTRW5ITVJ?
KYSE-180 NEmye4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jrdWlEPTB;MUKuPFEhdk1? M2TLXnNCVkeHUh?=
C8166 M4O0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDQOFVKSzVyPUGzMlA5KG6P NFHUSpBUSU6JRWK=
NCI-H460 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF|LkW0JI5O NET1RnVUSU6JRWK=
SNU-449 MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfJWXc2UUN3ME2xN{44PyCwTR?= MVnTRW5ITVJ?
MDA-MB-468 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LzXmlEPTB;MUSuNVIhdk1? MULTRW5ITVJ?
COR-L23 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvYTWM2OD1zND6xN{BvVQ>? NIfPSY1USU6JRWK=
CTV-1 NX;VOYozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPMTWM2OD1zND6xOEBvVQ>? Moe1V2FPT0WU
BL-41 NVXP[oxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfGbGdLUUN3ME2xOE4{PyCwTR?= M4jqTHNCVkeHUh?=
IGR-1 NIHIeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[5WVdnUUN3ME2xOE41OiCwTR?= M135bXNCVkeHUh?=
TK10 NHPhdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXVcZFKSzVyPUG0MlQ6KG6P NYq1UlFoW0GQR1XS
REH NYHD[WwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF2LkWxJI5O NETjRoNUSU6JRWK=
LU-139 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH30bHdKSzVyPUG0MlU6KG6P NF[wOWpUSU6JRWK=
KP-N-YS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\TOWlEPTB;MUSuPVchdk1? MUjTRW5ITVJ?
PANC-10-05 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF3LkO4JI5O NVjQNIN{W0GQR1XS
HL-60 M2\XZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2ye5FKSzVyPUG1MlY6KG6P MWLTRW5ITVJ?
T84 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF3Lkm2JI5O MUXTRW5ITVJ?
RPMI-8226 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LFT2lEPTB;MU[uNFIhdk1? NXO1enZDW0GQR1XS
UM-UC-3 NEPTbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXh[VF2UUN3ME2xOk4yPiCwTR?= MYXTRW5ITVJ?
TE-10 NUHmSoZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTjTWM2OD1zNj6yNUBvVQ>? NFTp[FVUSU6JRWK=
CAL-148 NFW0TFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fKNGlEPTB;MUeuNlMhdk1? MV3TRW5ITVJ?
BV-173 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF5LkK3JI5O M2X6WnNCVkeHUh?=
Calu-3 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP1TXBKSzVyPUG3MlI6KG6P MnrnV2FPT0WU
RPMI-2650 NXL0VFFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LTNGlEPTB;MUeuOVkhdk1? M4HOPXNCVkeHUh?=
MKN45 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLNTWM2OD1zNz63N{BvVQ>? MXLTRW5ITVJ?
NUGC-3 NHTFVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M164UWlEPTB;MUiuN|Qhdk1? MWnTRW5ITVJ?
NCI-H520 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF6Lke3JI5O NWLZdoIxW0GQR1XS
CCRF-CEM MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF6Lki1JI5O NU\qdWplW0GQR1XS
NCI-H2405 NG\OS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj4TWM2OD1zOT6xJI5O NYHOdGlGW0GQR1XS
ES7 NIry[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF7Lke2JI5O NY\oNoVTW0GQR1XS
BPH-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn4WnRQUUN3ME2yNE4zQCCwTR?= MU\TRW5ITVJ?
SAS NHrLRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPnV29nUUN3ME2yNE42KG6P NEm0SoJUSU6JRWK=
HuCCT1 M4D1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[3TWM2OD1{MD61PEBvVQ>? M4fwd3NCVkeHUh?=
LOUCY M3flemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfN[mVbUUN3ME2yNE43PiCwTR?= NWnjSW13W0GQR1XS
NCI-H292 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XHfWlEPTB;MkCuO|khdk1? M363d3NCVkeHUh?=
G-361 NEC3TJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETq[ndKSzVyPUKxMlA4KG6P NX\sXZB3W0GQR1XS
M059J NHLlVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlexTWM2OD1{MT6wPEBvVQ>? M2O4cXNCVkeHUh?=
NCI-H1651 MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX0TWM2OD1{MT6xNUBvVQ>? M4XQc3NCVkeHUh?=
KALS-1 M2LVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfhOIFKSzVyPUKxMlM6KG6P MkX2V2FPT0WU
DJM-1 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL3SHZKSzVyPUKxMlU6KG6P MV\TRW5ITVJ?
AU565 M1Xtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJzLkizJI5O NYP4VZJDW0GQR1XS
HCC38 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u1fGlEPTB;MkGuPVUhdk1? M4\WdHNCVkeHUh?=
U251 NIT5b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G3VGlEPTB;MkKuNlchdk1? M2G4NXNCVkeHUh?=
ABC-1 NUXQR5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vsRmlEPTB;MkKuOlUhdk1? MonTV2FPT0WU
SK-NEP-1 NVn4UFlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvFeJdiUUN3ME2yNk46OyCwTR?= MXnTRW5ITVJ?
CESS NIXINnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjXeopuUUN3ME2yN{4yQSCwTR?= M{O2O3NCVkeHUh?=
MIA-PaCa-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\PTWM2OD1{Mz6zOkBvVQ>? M{DqU3NCVkeHUh?=
SUP-T1 NVH2WIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfqWnhCUUN3ME2yN{41PyCwTR?= M1jpdXNCVkeHUh?=
L-428 NEj2emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfKSWtpUUN3ME2yN{43OiCwTR?= NFLwbZJUSU6JRWK=
SW954 NWTHR3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;xN4RKSzVyPUKzMlY5KG6P NXvMRWFGW0GQR1XS
HO-1-N-1 NYi3NZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj4TWM2OD1{Mz63O{BvVQ>? MoHWV2FPT0WU
CHP-126 M17O[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKxTWM2OD1{ND6xOEBvVQ>? NEDlbY1USU6JRWK=
HMV-II M2nSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nhb2lEPTB;MkSuN|Qhdk1? MoDrV2FPT0WU
NB10 M2D1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn73TWM2OD1{ND6zO{BvVQ>? NUHZSJI{W0GQR1XS
A172 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ2LkexJI5O MoHRV2FPT0WU
MONO-MAC-6 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ2Lki0JI5O M3eyeXNCVkeHUh?=
NCI-H1650 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH1UFJKSzVyPUK1MlQhdk1? MVTTRW5ITVJ?
NH-12 M2LyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DzNWlEPTB;MkWuOUBvVQ>? NF;zXVFUSU6JRWK=
ML-2 M33LSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PrS2lEPTB;MkWuO|Qhdk1? M1mxR3NCVkeHUh?=
MZ2-MEL M336W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJ4LkKyJI5O MnzEV2FPT0WU
COLO-684 NIrrUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[2TGlEPTB;Mk[uOFEhdk1? NW\xbIR[W0GQR1XS
HuP-T4 NEfRbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6zTWM2OD1{Nz6zJI5O MnX3V2FPT0WU
SW837 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv1So1SUUN3ME2yO{43OiCwTR?= M3\VTXNCVkeHUh?=
MDA-MB-231 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml2xTWM2OD1{Nz63PEBvVQ>? NFruO|lUSU6JRWK=
KYSE-140 M3n2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXBTWM2OD1{Nz65NUBvVQ>? NEi3VJJUSU6JRWK=
NOMO-1 M3TW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm4W4w1UUN3ME2yPE43QCCwTR?= M3fLR3NCVkeHUh?=
GP5d M1Hn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTzVpNKSzVyPUK4MlczKG6P M{LhT3NCVkeHUh?=
COR-L105 NVvwc45VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLVZnNzUUN3ME2yPU41OiCwTR?= MnjyV2FPT0WU
LS-411N NV\GWWlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ7Lki4JI5O MmXjV2FPT0WU
NY Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNyLkG4JI5O NEnxOYdUSU6JRWK=
NCI-H2030 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13E[WlEPTB;M{CuOFUhdk1? NV\DbZRCW0GQR1XS
CCF-STTG1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7wd5l7UUN3ME2zNU41OiCwTR?= MVHTRW5ITVJ?
NCI-H1703 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7qV3h7UUN3ME2zNU44QCCwTR?= MkjFV2FPT0WU
TUR M1Ppc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN{LkCzJI5O MVjTRW5ITVJ?
NOS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;s[nRKSzVyPUOyMlQ1KG6P NFTsUHRUSU6JRWK=
A2058 NHTrRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN{LkizJI5O MV\TRW5ITVJ?
LCLC-103H MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTN|LkK1JI5O NIrSNWNUSU6JRWK=
NCI-H510A MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELwellKSzVyPUOzMlI4KG6P M3vtUHNCVkeHUh?=
BC-1 M13JWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nLV2lEPTB;M{OuO|chdk1? M4e1enNCVkeHUh?=
SK-CO-1 NXm4TGlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XiO2lEPTB;M{SuNFEhdk1? MUDTRW5ITVJ?
A673 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH3WHRKSzVyPUO0MlE4KG6P MmjLV2FPT0WU
VM-CUB-1 NYLvXmJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\oeWlEPTB;M{SuOlkhdk1? NGPBNlFUSU6JRWK=
HH M2nUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki5TWM2OD1|NT6wOkBvVQ>? MkHIV2FPT0WU
CAL-27 M{W5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTN3LkG2JI5O NHHMR5FUSU6JRWK=
NEC8 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN3LkO3JI5O MkfHV2FPT0WU
BxPC-3 M3LV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjMU2pKSzVyPUO2MlkyKG6P MkjVV2FPT0WU
SNB75 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe5WGFVUUN3ME2zO{4zPCCwTR?= NGP1TY9USU6JRWK=
NB13 NWLMWoh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN6LkKzJI5O NVPuTHNqW0GQR1XS
SK-OV-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN6Lke0JI5O NXnob4JSW0GQR1XS
ME-180 NGrEUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPNZZFrUUN3ME2zPE45KG6P NHjoOppUSU6JRWK=
JiyoyeP-2003 M1PkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrzVXBrUUN3ME2zPU4{QCCwTR?= NXfV[G8yW0GQR1XS
LU-134-A NVTKeod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL6TWM2OD12MD6wNkBvVQ>? NXv6e4czW0GQR1XS
LS-123 NY\GTY9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTRyLkK4JI5O M1j5NHNCVkeHUh?=
COLO-800 NInSWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRyLkW2JI5O M4KzdnNCVkeHUh?=
LB831-BLC MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTRzLki1JI5O Mn;JV2FPT0WU
NCI-H747 NVe4fHJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r5OWlEPTB;NEKuNlghdk1? NVXhZo1CW0GQR1XS
MZ7-mel MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LaSWlEPTB;NEKuOlYhdk1? M4G0dXNCVkeHUh?=
GT3TKB M3rCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjNNplYUUN3ME20Nk44OiCwTR?= NH7CeIpUSU6JRWK=
MOLT-16 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnQZWRKSzVyPUSzMlA2KG6P M{XYWnNCVkeHUh?=
23132-87 NH[xWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPBclVKSzVyPUSzMlA2KG6P M1\zVHNCVkeHUh?=
PF-382 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnKeVBKUUN3ME20OE4zOiCwTR?= MkTIV2FPT0WU
ES3 M1;sSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nyT2lEPTB;NESuOkBvVQ>? MU\TRW5ITVJ?
SW756 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlznTWM2OD12NT6xOEBvVQ>? M2PiPHNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 15 mg/mL (56.99 mM)
Water 14 mg/mL warmed (53.19 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
water warming
14mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
保管
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis信号経路図

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID